ERBB2 and breast carcinoma: Research has indicated that when T-DM1 is combined with docetaxel in HER2-positive breast cancer patients, dose-related toxicity and adverse events occur in 80% of patients, including leukopenia, epistaxis, nausea, and diarrhea (89).